Is Cytokinetics, Incorporated (CYTK) a Buy, Sell, or Hold?
Cytokinetics, Incorporated
NASDAQ:CYTK
$81.5379 USD
-$0.39 (-0.48%)
- Volume
- 36.76K
- Average Volume
- 2.62M
- Market Capitalization
- $10.15B
- P/E Ratio
- -11.94
- Dividend Yield
- 0.00%
- Price Target
- $108.00
- Year High
- $88.31
- Year Low
- $32.89
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.21
NUMBER OF INSIDERS BUYING (LAST 12 MONTHS)
115
NUMBER OF INSIDERS SELLING (LAST 12 MONTHS)
137
AMOUNT OF INSIDER SELLING (LAST 12 MONTHS)
$ 1.06M
CYTK Estimated and Actual Revenue by Quarter
Get MSFT Insider Trade Alerts
CYTK Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Blum Robert I | director, officer: President & CEO | 2026-07-13 | M-Exempt | 10.6 | 2026-07-14 |
| Blum Robert I | director, officer: President & CEO | 2026-07-13 | S-Sale | 82.02 | 2026-07-14 |
| Blum Robert I | director, officer: President & CEO | 2026-07-13 | M-Exempt | 10.6 | 2026-07-14 |
| Malik Fady Ibraham | officer: EVP Research & Development | 2026-07-07 | M-Exempt | 7.8 | 2026-07-07 |
| Malik Fady Ibraham | officer: EVP Research & Development | 2026-07-07 | S-Sale | 86.62 | 2026-07-07 |
| Malik Fady Ibraham | officer: EVP Research & Development | 2026-07-07 | M-Exempt | 7.8 | 2026-07-07 |
| Blum Robert I | director, officer: President & CEO | 2026-07-01 | S-Sale | 84.92 | 2026-07-02 |
| Callos Andrew | officer: EVP, Chief Commercial Officer | 2026-07-01 | M-Exempt | 23.26 | 2026-07-02 |
| Callos Andrew | officer: EVP, Chief Commercial Officer | 2026-07-01 | S-Sale | 85.8 | 2026-07-02 |
| Callos Andrew | officer: EVP, Chief Commercial Officer | 2026-07-01 | M-Exempt | 23.26 | 2026-07-02 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-07-01 | M-Exempt | 48.51 | 2026-07-02 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-07-01 | S-Sale | 87.79 | 2026-07-02 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-07-01 | M-Exempt | 48.51 | 2026-07-02 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-24 | M-Exempt | 48.51 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-24 | M-Exempt | 44.36 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-24 | M-Exempt | 44.36 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-24 | M-Exempt | 48.51 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-24 | M-Exempt | 44.36 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-24 | M-Exempt | 44.36 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-24 | M-Exempt | 48.51 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-24 | S-Sale | 82.3 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-24 | M-Exempt | 44.36 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-24 | M-Exempt | 44.36 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-24 | M-Exempt | 48.51 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-24 | M-Exempt | 48.51 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-24 | M-Exempt | 48.51 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-24 | M-Exempt | 44.36 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-24 | M-Exempt | 44.36 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-29 | M-Exempt | 44.36 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-29 | M-Exempt | 44.36 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-29 | M-Exempt | 48.51 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-29 | M-Exempt | 44.36 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-29 | M-Exempt | 44.36 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-29 | S-Sale | 85 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-29 | M-Exempt | 48.51 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-29 | M-Exempt | 44.36 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-29 | M-Exempt | 44.36 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-29 | M-Exempt | 44.36 | 2026-06-29 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-06-29 | M-Exempt | 44.36 | 2026-06-29 |
| Malik Fady Ibraham | officer: EVP Research & Development | 2026-06-23 | M-Exempt | 7.8 | 2026-06-23 |
| Malik Fady Ibraham | officer: EVP Research & Development | 2026-06-23 | S-Sale | 79.51 | 2026-06-23 |
| Malik Fady Ibraham | officer: EVP Research & Development | 2026-06-23 | M-Exempt | 7.8 | 2026-06-23 |
| Blum Robert I | director, officer: President & CEO | 2026-06-15 | S-Sale | 70.46 | 2026-06-15 |
| Malik Fady Ibraham | officer: EVP Research & Development | 2026-06-09 | M-Exempt | 7.8 | 2026-06-09 |
| Malik Fady Ibraham | officer: EVP Research & Development | 2026-06-09 | S-Sale | 67.98 | 2026-06-09 |
| Malik Fady Ibraham | officer: EVP Research & Development | 2026-06-09 | M-Exempt | 7.8 | 2026-06-09 |
| Kaye Edward M. MD | director | 2026-06-01 | S-Sale | 76.09 | 2026-06-01 |
| Callos Andrew | officer: EVP, Chief Commercial Officer | 2026-06-01 | M-Exempt | 23.26 | 2026-06-01 |
| Callos Andrew | officer: EVP, Chief Commercial Officer | 2026-06-01 | S-Sale | 74.08 | 2026-06-01 |
| Callos Andrew | officer: EVP, Chief Commercial Officer | 2026-06-01 | M-Exempt | 23.26 | 2026-06-01 |
| PARSHALL B LYNNE | director | 2026-06-01 | S-Sale | 74.08 | 2026-06-01 |
| Blum Robert I | director, officer: President & CEO | 2026-05-27 | S-Sale | 77.21 | 2026-05-28 |
| Bhanji Muna | director | 2026-05-27 | A-Award | 0 | 2026-05-27 |
| Bhanji Muna | director | 2026-05-27 | A-Award | 77.15 | 2026-05-27 |
| Daly James M | director | 2026-05-27 | A-Award | 77.15 | 2026-05-27 |
| Daly James M | director | 2026-05-27 | A-Award | 0 | 2026-05-27 |
| Harrington Robert Arthur | director | 2026-05-27 | A-Award | 0 | 2026-05-27 |
| Harrington Robert Arthur | director | 2026-05-27 | A-Award | 77.15 | 2026-05-27 |
| HENDERSON JOHN T | director | 2026-05-27 | A-Award | 0 | 2026-05-27 |
| HENDERSON JOHN T | director | 2026-05-27 | A-Award | 77.15 | 2026-05-27 |
| Kaye Edward M. MD | director | 2026-05-27 | A-Award | 0 | 2026-05-27 |
| Kaye Edward M. MD | director | 2026-05-27 | A-Award | 77.15 | 2026-05-27 |
| PARSHALL B LYNNE | director | 2026-05-27 | A-Award | 0 | 2026-05-27 |
| PARSHALL B LYNNE | director | 2026-05-27 | A-Award | 77.15 | 2026-05-27 |
| Landry Robert E | director | 2026-05-27 | A-Award | 0 | 2026-05-27 |
| Landry Robert E | director | 2026-05-27 | A-Award | 77.15 | 2026-05-27 |
| WIERENGA WENDELL | director | 2026-05-27 | A-Award | 0 | 2026-05-27 |
| WIERENGA WENDELL | director | 2026-05-27 | A-Award | 77.15 | 2026-05-27 |
| Wysenski Nancy | director | 2026-05-27 | A-Award | 0 | 2026-05-27 |
| Wysenski Nancy | director | 2026-05-27 | A-Award | 77.15 | 2026-05-27 |
| Malik Fady Ibraham | officer: EVP Research & Development | 2026-05-19 | M-Exempt | 7.8 | 2026-05-20 |
| Malik Fady Ibraham | officer: EVP Research & Development | 2026-05-19 | S-Sale | 75.69 | 2026-05-20 |
| Malik Fady Ibraham | officer: EVP Research & Development | 2026-05-19 | M-Exempt | 7.8 | 2026-05-20 |
| Blum Robert I | director, officer: President & CEO | 2026-05-14 | S-Sale | 77.92 | 2026-05-14 |
| Malik Fady Ibraham | officer: EVP Research & Development | 2026-05-05 | M-Exempt | 7.8 | 2026-05-05 |
| Malik Fady Ibraham | officer: EVP Research & Development | 2026-05-05 | S-Sale | 77.37 | 2026-05-05 |
| Malik Fady Ibraham | officer: EVP Research & Development | 2026-05-05 | M-Exempt | 7.8 | 2026-05-05 |
| WIERENGA WENDELL | director | 2026-05-05 | M-Exempt | 12.4 | 2026-05-05 |
| WIERENGA WENDELL | director | 2026-05-05 | S-Sale | 75 | 2026-05-05 |
| WIERENGA WENDELL | director | 2026-05-05 | M-Exempt | 12.4 | 2026-05-05 |
| Lee Sung | officer: EVP, Chief Financial Officer | 2026-05-05 | S-Sale | 76.87 | 2026-05-05 |
| HENDERSON JOHN T | director | 2026-05-05 | M-Exempt | 7.61 | 2026-05-05 |
| HENDERSON JOHN T | director | 2026-05-05 | S-Sale | 75.97 | 2026-05-05 |
| HENDERSON JOHN T | director | 2026-05-05 | M-Exempt | 7.61 | 2026-05-05 |
| Callos Andrew | officer: EVP, Chief Commercial Officer | 2026-05-05 | M-Exempt | 39.13 | 2026-05-05 |
| Callos Andrew | officer: EVP, Chief Commercial Officer | 2026-05-05 | S-Sale | 77.25 | 2026-05-05 |
| Callos Andrew | officer: EVP, Chief Commercial Officer | 2026-05-05 | M-Exempt | 39.13 | 2026-05-05 |
| Callos Andrew | officer: EVP, Chief Commercial Officer | 2026-05-01 | M-Exempt | 37.63 | 2026-05-04 |
| Callos Andrew | officer: EVP, Chief Commercial Officer | 2026-05-01 | S-Sale | 65 | 2026-05-04 |
| Callos Andrew | officer: EVP, Chief Commercial Officer | 2026-05-01 | M-Exempt | 37.63 | 2026-05-04 |
| Callos Andrew | officer: EVP, Chief Commercial Officer | 2026-04-30 | M-Exempt | 23.26 | 2026-04-30 |
| Callos Andrew | officer: EVP, Chief Commercial Officer | 2026-04-30 | S-Sale | 63.26 | 2026-04-30 |
| Callos Andrew | officer: EVP, Chief Commercial Officer | 2026-04-30 | M-Exempt | 23.26 | 2026-04-30 |
| Blum Robert I | director, officer: President & CEO | 2026-04-29 | S-Sale | 59.62 | 2026-04-29 |
| Malik Fady Ibraham | officer: EVP Research & Development | 2026-04-21 | M-Exempt | 7.8 | 2026-04-21 |
| Malik Fady Ibraham | officer: EVP Research & Development | 2026-04-21 | S-Sale | 65.69 | 2026-04-21 |
| Malik Fady Ibraham | officer: EVP Research & Development | 2026-04-21 | M-Exempt | 7.8 | 2026-04-21 |
| Wysenski Nancy | director | 2026-04-15 | A-Award | 65.37 | 2026-04-15 |
| WIERENGA WENDELL | director | 2026-04-15 | A-Award | 65.37 | 2026-04-15 |
| Kaye Edward M. MD | director | 2026-04-15 | A-Award | 65.37 | 2026-04-15 |